Abstract
It is well known that there are many mediators which are important in the generation and execution of immune responses. These mediators, when generated by lymphoid cells or when acting on lymphoid targets, have been termed lymphokines and those acting on non-lymphoid targets have been named cytokines. The combination term “lymphokine/cytokine” has been used to refer to the general class of soluble substances mediating biological responses in cell-cell interactions. These substances are distinct from, although similar to, hormones which are generally secreted by cells within the endocrine system acting on a remote target.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
R. K. Oldham, Biologicals and biological response modifiers: fourth modality of cancer treatment, Cancer Treat. Rpt. 68 (1): 221 (1984).
B. H. Waksman, Overview: biology of the lymphokines, in: “Biology of Lymphokines,” eds., Academic Press (1979).
R. K. Oldham, G. N. Thurman, J. E. Talmadge, et al., Lymphokines, monoclonal antibodies and other biological response modifiers in the treatment of cancer, Cancer 1(54) (Supp. 11 ): 2795 (1984).
R. K. Oldham, Biological response modifiers program, Biol. Resp. Modif. 1: 81 (1982).
I. J. Fidler, M. Berendt, and R. K. Oldham, The rationale for design of screening assays for the assessment of biological response modifiers for cancer treatment, J. Biol. Resp. Modif. 1: 15 (1982).
J. E. Talmadge, R. K. Oldham, and I. J. Fidler, Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers, J. Biol. Resp. Modif. 3: 88 (1984).
N. Flomenberg, K. Welte, R. Mertelsmann, et al., Immunologic effects of interleukin 2 in primary immunodeficiency diseases. IV. J. Immunol. 130: 2644 (1983).
S. A. Sherwin, J. A. Knost, S. Fein, et al., A multiple dose phase I trial of recombinant leukocyte A interferon in cancer patients, JAMA 248: 2461 (1982).
S. A. Sherwin, J. A. Knost, S. Fein, et al., A multiple dose phase I trial of recombinant leukocyte A interferon in cancer patients, JAMA 248: 2461 (1982).
K. A. Foon, S. A. Sherwin, P. G. Abrams, et al., Recombinant leukocyte A interferon: an effective agent for the treatment of advanced non-Hodgkin’s lymphoma, N. Eng. J. Med. 311 (18): 1148 (1984).
P. A. Bunn, Jr., K. A. Foon, D. C. Idhe, et al., Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas, Annals Int. Med. 101 (4): 484 (1984).
J. M. Kirkwood and M. S. Ernstoff, Interferons in the treatment of human cancer, J. Clin. Oncol. 2: 336 (1984).
R. K. Oldham, Monoclonal antibodies in cancer therapy, J. Clin. Oncol. 1: 582 (1983).
R. K. Oldham, K. A. Foon, A. C. Morgan, et al., Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration, Clin. Oncol. 2 (11): 1235 (1984).
A. B. Cosimi, R. B. Colvin, R. C. Burton, et al., Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts, N. Eng. J. Med. 305: 308 (1981).
K. A. Foon, R. W. Schroff, P. A. Bunn, et al., Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia, Blood 64 (5): 1085 (1984).
R. W. Schroff, K. A. Foon, S. B. Wilburn, et al., Human antimurine immunoglobulin responses in patients receiving monoclonal antibody therapy, Cancer Res. 45 (2): 879 (1985).
R. A. Miller, D. G. Maloney, R. Warnke, et al., Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody, N. Eng. J. Med. 306: 517 (1982).
S. L. Giardina, R. W. Schroff, C. S. Woodhouse, et al., Detection of two distinct malignant B-cell clones in a single patient using anti-idiotype monoclonal antibodies and immunoglobulin in gene rearrangement, (submitted, 1984 ).
R. K. Oldham and R. V. Smalley, Immunotherapy: the old and the new, J. Biol. Resp. Modif. 2: 1 (1983).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Oldham, R.K. (1986). Immunorestoration of Immunodeficiency by Biological Response Modifiers. In: Szentivanyi, A., Friedman, H. (eds) Viruses, Immunity, and Immunodeficiency. University of South Florida International Biomedical Symposia Series. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2185-9_26
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2185-9_26
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9286-9
Online ISBN: 978-1-4613-2185-9
eBook Packages: Springer Book Archive